Posts Tagged ‘price’
Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review … – Nature.com
Araujo AB, ODonnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:59206. https://doi.org/10.1210/jc.2003-031719
Article CAS PubMed Google Scholar
Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:7629. https://doi.org/10.1111/j.1742-1241.2006.00992.x
Article CAS PubMed Google Scholar
Thirumavalavan N, Scovell JM, Link RE, Lamb DJ, Lipshultz LI. Does solid organ transplantation affect male reproduction? Eur Urol Focus. 2018;4:30710. https://doi.org/10.1016/j.euf.2018.08.012
Article PubMed PubMed Central Google Scholar
Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Brny P, et al. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol. 2009;20:61320. https://doi.org/10.1681/ASN.2008060664
Article CAS PubMed PubMed Central Google Scholar
Wachterman MW, OHare AM, Rahman O-K, Lorenz KA, Marcantonio ER, Alicante GK, et al. One-year mortality after dialysis initiation among older adults. JAMA Intern Med. 2019;179:98790. https://doi.org/10.1001/jamainternmed.2019.0125
Article PubMed PubMed Central Google Scholar
Kazemeini SM, Mogharabian N, Asadpour A, Naderi G, Kasaeian A, Mousavi A. The effect of renal transplant on hypogonadism and erectile dysfunction due to end-stage renal disease. Saudi J Kidney Dis Transplant. 2021;32:9238. https://doi.org/10.4103/1319-2442.338303
Article Google Scholar
Akbari F, Alavi M, Esteghamati A, Mehrsai A, Djaladat H, Zohrevand R, et al. Effect of renal transplantation on sperm quality and sex hormone levels. BJU Int. 2003;92:2813. https://doi.org/10.1046/j.1464-410x.2003.04323.x
Article CAS PubMed Google Scholar
Reinhardt W, Kbber H, Dolff S, Benson S, Fhrer D, Tan S. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine. 2018;60:15966. https://doi.org/10.1007/s12020-018-1543-2
Article CAS PubMed Google Scholar
Saha M-T, Saha HHT, Niskanen LK, Salmela KT, Pasternack AI. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002;92:7357. https://doi.org/10.1159/000064079
Article CAS PubMed Google Scholar
Shoskes DA, Kerr H, Askar M, Goldfarb DA, Schold J. Low testosterone at time of transplantation is independently associated with poor patient and graft survival in male renal transplant recipients. J Urol. 2014;192:116871. https://doi.org/10.1016/j.juro.2014.03.102
Article CAS PubMed Google Scholar
UNOS Data and Transplant Statistics | Organ Donation Data. UNOS. https://unos.org/data/. Accessed 3 February 2024.
Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389:10717. https://doi.org/10.1056/NEJMoa2215025
Article CAS PubMed Google Scholar
Antonucci M, Palermo G, Recupero SM, Bientinesi R, Presicce F, Foschi N, et al. Male sexual dysfunction in patients with chronic end-stage renal insufficiency and in renal transplant recipients. Arch Ital Urol Androl. 2016;87:299305. https://doi.org/10.4081/aiua.2015.4.299
Article PubMed Google Scholar
Miner MM, Khera M, Bhattacharya RK, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med. 2011;123:1727. https://doi.org/10.3810/pgm.2011.05.2280
Article PubMed Google Scholar
Cha J, Han D. Health-related quality of life based on comorbidities among patients with end-stage renal disease. Osong Public Health Res Perspect. 2020;11:194200. https://doi.org/10.24171/j.phrp.2020.11.4.08
Article PubMed PubMed Central Google Scholar
Albaaj F, Sivalingham M, Haynes P, McKinnon G, Foley RN, Waldek S, et al. Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J. 2006;82:6936. https://doi.org/10.1136/pgmj.2006.045963
Article CAS PubMed PubMed Central Google Scholar
Balczar-Hernndez L, Mendoza-Zubieta V, Gonzlez-Virla B, Gonzlez-Garca B, Osorio-Olvera M, Pealoza-Juarez JU, et al. Hypothalamic-pituitary-gonadal axis disturbance and its association with insulin resistance in kidney transplant recipients. J Bras Nefrol. 2023;45:7783. https://doi.org/10.1590/2175-8239-JBN-2021-0250en
Article PubMed Google Scholar
Stenvinkel P. Inflammation in end-stage renal disease: the hidden enemy. Nephrology. 2006;11:3641. https://doi.org/10.1111/j.1440-1797.2006.00541.x
Article PubMed Google Scholar
Wibullaksanakul S, Handelsman DJ. Regulation of hypothalamic gonadotropin-releasing hormone secretion in experimental uremia: in vitro studies. Neuroendocrinology. 1991;54:3538. https://doi.org/10.1159/000125913
Article CAS PubMed Google Scholar
Dong QH, Handelsman DJ. Regulation of pulsatile luteinizing hormone secretion in experimental uremia. Endocrinology. 1991;128:121822. https://doi.org/10.1210/endo-128-3-1218
Article CAS PubMed Google Scholar
Lim VS, Henriquez C, Sievertsen G, Frohman LA. Ovarian function in chronic renal failure: evidence suggesting hypothalamic anovulation. Ann Intern Med. 1980;93:217. https://doi.org/10.7326/0003-4819-93-1-21
Article CAS PubMed Google Scholar
Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol. 1996;78:6358. https://doi.org/10.1046/j.1464-410x.1996.14624.x
Article CAS PubMed Google Scholar
Levitan D, Moser SA, Goldstein DA, Kletzky OA, Lobo RA, Massry SG. Disturbances in the hypothalamic-pituitary-gonadal axis in male patients with acute renal failure. Am J Nephrol. 1984;4:99106. https://doi.org/10.1159/000166785
Article CAS PubMed Google Scholar
Distiller LA, Morley JE, Sagel J, Pokroy M, Rabkin R. Pituitary-gonadal function in chronic renal failure: the effect of luteinizing hormone-releasing hormone and the influence of dialysis. Metabolism. 1975;24:71120. https://doi.org/10.1016/0026-0495(75)90039-6
Article CAS PubMed Google Scholar
Biasioli S, Mazzali A, Foroni R, DAndrea G, Feriani M, Chiaramonte S, et al. Chronobiological variations of prolactin (PRL) in chronic renal failure (CRF). Clin Nephrol. 1988;30:8692.
CAS PubMed Google Scholar
Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin J Am Soc Nephrol. 2012;7:20715. https://doi.org/10.2215/CJN.06840711
Article CAS PubMed PubMed Central Google Scholar
Adachi N, Lei B, Deshpande G, Seyfried FJ, Shimizu I, Nagaro T, et al. Uraemia suppresses central dopaminergic metabolism and impairs motor activity in rats. Intensive Care Med. 2001;27:165560. https://doi.org/10.1007/s001340101067
Article CAS PubMed Google Scholar
Sievertsen GD, Lim VS, Nakawatase C, Frohman LA. Metabolic clearance and secretion rates of human prolactin in normal subjects and in patients with chronic renal failure. J Clin Endocrinol Metab. 1980;50:84652. https://doi.org/10.1210/jcem-50-5-846
Article CAS PubMed Google Scholar
Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 2011;26:18490. https://doi.org/10.1093/ndt/gfq397
Article CAS PubMed Google Scholar
Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91:4599602. https://doi.org/10.1210/jc.2006-0763
Article CAS PubMed Google Scholar
Nilsson E, Stenvinkel P, Liu S, Stedman MR, Chertow GM, Floege J. Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial. Nephrol Dial Transplant. 2023;38:151927. https://doi.org/10.1093/ndt/gfac278
Article CAS PubMed Google Scholar
Rymarz A, Matyjek A, Gomka M, Niemczyk S. Lean tissue index and body cell mass can be predictors of low free testosterone levels in men on hemodialysis. J Ren Nutr. 2019;29:52935. https://doi.org/10.1053/j.jrn.2019.03.078
Article CAS PubMed Google Scholar
Cobo G, Gallar P, Di Gioia C, Garca Lacalle C, Camacho R, Rodriguez I, et al. Hypogonadism associated with muscle atrophy, physical inactivity and ESA hyporesponsiveness in men undergoing haemodialysis. Nefrologia. 2017;37:5460. https://doi.org/10.1016/j.nefro.2016.04.009
Article PubMed Google Scholar
Park MG, Koo HS, Lee B. Characteristics of testosterone deficiency syndrome in men with chronic kidney disease and male renal transplant recipients: a cross-sectional study. Transplant Proc. 2013;45:29704. https://doi.org/10.1016/j.transproceed.2013.08.087
Article CAS PubMed Google Scholar
Skiba R, Rymarz A, Matyjek A, Dymus J, Woniak-Kosek A, Syryo T, et al. Testosterone replacement therapy in chronic kidney disease patients. Nutrients. 2022;14:3444. https://doi.org/10.3390/nu14163444
Article CAS PubMed PubMed Central Google Scholar
Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:42332. https://doi.org/10.1016/j.juro.2018.03.115
Article PubMed Google Scholar
Brock G, Heiselman D, Maggi M, Kim SW, Rodrguez Vallejo JM, Behre HM, et al. Effect of testosterone solution 2% on testosterone concentration, sex drive and energy in hypogonadal men: results of a placebo controlled study. J Urol. 2016;195:699705. https://doi.org/10.1016/j.juro.2015.10.083
Article CAS PubMed Google Scholar
Maggi M, Heiselman D, Knorr J, Iyengar S, Paduch DA, Donatucci CF. Impact of testosterone solution 2% on ejaculatory dysfunction in hypogonadal men. J Sex Med. 2016;13:12206. https://doi.org/10.1016/j.jsxm.2016.05.012
Article PubMed Google Scholar
Roy CN, Snyder PJ, Stephens-Shields AJ, Artz AS, Bhasin S, Cohen HJ, et al. Association of testosterone levels with anemia in older men: a controlled clinical trial. JAMA Intern Med. 2017;177:48090. https://doi.org/10.1001/jamainternmed.2016.9540
Article PubMed PubMed Central Google Scholar
Svartberg J, Agledahl I, Figenschau Y, Sildnes T, Waterloo K, Jorde R. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20:37887. https://doi.org/10.1038/ijir.2008.19
Article CAS PubMed Google Scholar
Cherrier MM, Anderson K, Shofer J, Millard S, Matsumoto AM. Testosterone treatment of men with mild cognitive impairment and low testosterone levels. Am J Alzheimers Dis Other Demen. 2015;30:42130. https://doi.org/10.1177/1533317514556874
Article CAS PubMed Google Scholar
Vaughan C, Goldstein FC, Tenover JL. Exogenous testosterone alone or with finasteride does not improve measurements of cognition in healthy older men with low serum testosterone. J Androl. 2007;28:87582. https://doi.org/10.2164/jandrol.107.002931
Article CAS PubMed Google Scholar
Grossmann M, Hoermann R, Wittert G, Yeap BB. Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: a systematic review and meta-analysis of randomized controlled clinical trials. Clin Endocrinol. 2015;83:34451. https://doi.org/10.1111/cen.12664
Article CAS Google Scholar
Barton CH, Mirahmadi MK, Vaziri ND. Effects of long-term testosterone administration on pituitary-testicular axis in end-stage renal failure. Nephron. 1982;31:614. https://doi.org/10.1159/000182618
Article CAS PubMed Google Scholar
van Coevorden A, Stolear JC, Dhaene M, van Herweghem JL, Mockel J. Effect of chronic oral testosterone undecanoate administration on the pituitary-testicular axes of hemodialyzed male patients. Clin Nephrol. 1986;26:4854.
PubMed Google Scholar
Pechersky AV, Mazurov VI, Semiglazov VF, Karpischenko AI, Mikhailichenko VV, Udintsev AV. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002;25:11925. https://doi.org/10.1046/j.1365-2605.2002.00335.x
Article CAS PubMed Google Scholar
Pizzol D, Xiao T, Yang L, Demurtas J, McDermott D, Garolla A, et al. Prevalence of erectile dysfunction in patients with chronic kidney disease: a systematic review and meta-analysis. Int J Impot Res. 2021;33:50815. https://doi.org/10.1038/s41443-020-0295-8
Article PubMed Google Scholar
Lawrence IG, Price DE, Howlett TA, Harris KP, Feehally J, Walls J. Correcting impotence in the male dialysis patient: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis. 1998;31:3139. https://doi.org/10.1053/ajkd.1998.v31.pm9469503
Article CAS PubMed Google Scholar
Chatterjee R, Wood S, McGarrigle HH, Lees WR, Ralph DJ, Neild GH. A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. J Fam Plann Reprod Health Care. 2004;30:8890. https://doi.org/10.1783/147118904322995438
Article PubMed Google Scholar
Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract. 2017;23:55765. https://doi.org/10.4158/EP161665.OR
Article PubMed Google Scholar
Gronski MA, Grober ED, Gottesman IS, Ormsby RW, Bryson N. Efficacy of nasal testosterone gel (Natesto) stratified by baseline endogenous testosterone levels. J Endocr Soc. 2019;3:165262. https://doi.org/10.1210/js.2019-00183
Go here to read the rest:
Testosterone deficiency in men with end stage renal disease and kidney transplantation: a narrative review ... - Nature.com
Being prepared for the future – DVM 360
Sponsored by Embark
Adam Christman, DVM, MBA: We talk a lot now about spectrum of care. What happens to the dog parents, unfortunately, who cannot afford the price of DNA testing? We really want to recommend it, but they just dont have the funds. What are your thoughts on that?
Jenna Dockweiler, MS, DVM, DACT, CCRT, CVAT: DNA testing is fairly cost effective and it will only become more so in the future. A dog's DNA is the same from the day it's born to the last day of that pet's life. So really at any point along that journey, it is appropriate to DNA test. Potentially in the future, as costs come down with just the testing technology itself, it will likely become more accessible for those folks.
Adam Christman, DVM, MBA: What about the practice that says, "We don't have the time for this?
Lindsey Kock, DVM: I think it's one of those things that taking the time to do that DNA test enables you to have more time later. By taking the time to do that test, you no longer have a full laundry list of things to cover at that puppy exam, but you have a few individual talking points.
We talked about compliance, but if you have the genetic testing to back up the recommendations, you're spending less time teaching and helping the pet parent to understand those things that come up. Something that really is a pretty quick, minimally invasive test, the results can be a lot, but Embarks done a great job of whittling down those results. You take that and you save yourself time in the long run. So it's a little effort for, I think, a huge increased efficiency and increased payoff in the long run.
Adam Christman, DVM, MBA: Okay, are there specific dog breeds that, I don't want to say they have predispositions, but need DNA testing more than other dog breeds out there?
Jenna Dockweiler, MS, DVM, DACT, CCRT, CVAT: We all know there are certain breeds predisposed to certain genetic conditions. I think that's a known truth at this point in veterinary medicine, but certainly testing is appropriate for every dog at every age. Even conditions that we see or think of as particularly breed-associated may not be as breed-associated as we thought, which the urate stones would be a great example of something like that.
And the dog's DNA is going to be the same from when it's born to the last day of that pet's life. So you can test it anytime during that spectrum. And some of these diseases won't manifest until later in life.
Adam Christman, DVM, MBA: I want to talk a little bit about taking away some of the financial issues or burdens that can happen. I find, personally, when you DNA test these dogs and puppies that are coming in, that the clients are more likely to say, oh, let me get pet insurance, just to help take away some of that financial stress that can happen down the road. Have you experienced that in your neck of the woods?
Lindsey Kock, DVM: Yeah, it'll be interesting to see how genetic results have an impact on health insurance. I think today, genetic results are really giving us more insight into potential issues down the road, right? And I think a lot of insurance coverage to my knowledge is based on actual diagnosed conditions that we're seeing clinical signs for, but using some caution too in that and potentially getting the insurance on board first and then doing the genetic test may not be a bad idea.
But I think too, aside from insurance, just being able to be financially prepared for decisions that you may have to make down the road, right? So we talked about intervertebral disc disease (IVDD) with those at an increased risk. Dogs who have at least one of those mutations tend to be at like 45 fold more increased risk of having an episode, but also out of five to 15 increased risk for needing surgery, right? So being able to prepare early for that financial burden and being able to be prepared for that decision, whether you're saving up or you have insurance is really important.
Adam Christman, DVM, MBA: I know we chatted a few years ago about this and I'll share the story with all of you out here because some of you, probably all of you, know I'm a huge dashchund fan. I did want to do the DNA testing for Clark W. Griswald and Lindsay was the one to say you really should, just so that way you know if there's the marker. Well, lo and behold, he did, and this past summer he did have inner vertebral disc disease. He did fantastic, but I expected it. I had pet insurance for him. Granted, I'm his veterinarian, but I can't do the surgery, but it made me so much more aware as a dog dad, knowing like, okay, I know what's gonna happen as much as I had dog ramps, and anything that you try to do. I didn't have that huge panic feeling especially with IVDD when the dogs go down.
Lindsey Kock, DVM: It is hard. Yes, like I don't care who you are. Getting a dog to keep quiet is hard.
Adam Christman, DVM, MBA: I remember talking to clients in the exam room about this with IVDD just because it could be so scary to see your dog walking all of a sudden just go down. But I tell them to be prepared, just like you were talking about, just to know what to expect in case. And I have noticed in my experience that these clients, they're more responsible with the decision-making. Yes, they're emotional, but not nearly as emotional because we already had that discussion. Have you heard that too exactly?
Jenna Dockweiler, MS, DVM, DACT, CCRT, CVAT: Exactly. It's a more proactive discussion, like we were talking about earlier, rather than reactive. So you can tell this client, hey, this is what you're gonna look out for. Maybe they're gonna be wobbly in their hind end, have some back pain, or maybe, go all the way down. They're not panicked about what could this be. It's already, I have a good idea of what this might be and I know I need to seek veterinary attention.
Adam Christman, DVM, MBA: Yes, absolutely.
Excerpt from:
Being prepared for the future - DVM 360